🇺🇸 FDA
Pipeline program

Asundexian (BAY2433334)

19767

Phase 3 small_molecule terminated

Quick answer

Asundexian (BAY2433334) for Prevention of Stroke or Systemic Embolism is a Phase 3 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bayer HealthCare AG
Indication
Prevention of Stroke or Systemic Embolism
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials